Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05655702

DRug Use & Infections in ViEtnam: TuBerculosis Control

DRug Use & Infections in ViEtnam: TuBerculosis Control Towards Tuberculosis Elimination Among People Who Inject Drugs: Evaluation of a Community-based Intervention in Vietnam

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
4,000 (estimated)
Sponsor
ANRS, Emerging Infectious Diseases · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The overarching purpose of the proposed research is to demonstrate that a targeted, multi-component community-based intervention among PWID in Hai Phong will decrease TB prevalence among this very high-risk population.

Detailed description

Vietnam has a strong National TB Program (NTP), but it belongs to the 20 countries with the highest TB burden in the world. A TB prevalence study among people who inject drugs (PWID) was conducted as part of the Drug use \& Infections in ViEtnam (DRIVE) program, in collaboration with a local screening initiative (Zero TB Vietnam, national TB program - NTP) in 2018 in Hai Phong. While the annual TB rate in the general population of Vietnam is 0.13%, this study found an alarming prevalence of confirmed TB cases from 1.8% to 5.6% among PWID. Some populations, such as people who inject drugs (PWID), combine a very high risk of TB and low access to TB care. Based on the investigators experience in operational research among PWID and their expertise in TB, they designed an intervention to end TB among a highly vulnerable population such as PWID, through significant community involvement. They hypothesize that a targeted, multi-component community-based intervention among PWID in Hai Phong will decrease TB prevalence among this very high-risk population. The DRIVE-TB intervention will use four repeated large-scale randomized driven sampling surveys (RDSS) to identify TB-infected PWID in the community. During RDSS 1 and 4 all participants will undergo a questionnaire on TB symptoms, and have CRP, chest X-ray, and sputum collection for Xpert MTB-RIF®. In RDSS 2 and 3, participants will be screened through the best screening algorithm (elaborated in RDSS1). Participants from all RDSS will also be screened for LTBI through Tuberculin Skin Test (TST). Moreover the 3HP ancillary study, a therapeutic cohort will assess the acceptability, safety, adherence, and cost of a 12-dose once-weekly regimen of isoniazid/rifapentine (3HP) to prevent TB disease among RDSS 2 participants with a positive QuantiFERON test result will be assessed.

Conditions

Interventions

TypeNameDescription
OTHERCommunity based TB intervention* 3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening * A PWID-specific Information and communication (I\&C) TB module to improve PWID awareness about TB, * Peer group support to facilitate TB treatment initiation and retention, * Implementation of a peer support contact tracing and screening for active TB in contacts.

Timeline

Start date
2023-10-02
Primary completion
2025-11-01
Completion
2025-11-01
First posted
2022-12-19
Last updated
2025-01-30

Locations

2 sites across 1 country: Vietnam

Source: ClinicalTrials.gov record NCT05655702. Inclusion in this directory is not an endorsement.